Britain without the EMABMJ 2017; 357 doi: https://doi.org/10.1136/bmj.j2168 (Published 17 May 2017) Cite this as: BMJ 2017;357:j2168
Many people were surprised when they woke on 24 June 2016 to find the UK had voted to leave the European Union, but few were as shocked as those whose job it is to license drugs and keep track of their adverse effects. The vote meant that the European Medicines Agency would have to relocate from London and that UK pharmacovigilance specialists faced an uncertain future.
In the big political picture, these are footnotes. There are, remarked Saad Shakir, director of the Drug Safety Research Unit, at a forum the unit held in London on 26 April, probably 100 other niche areas of professional life where Brexit will impose changes as large or larger. But in the clamour over trade deals, immigration, and the role of the European Court of Justice, the small corners risk …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial